Analysts Offer Predictions for Aytu BioPharma Q1 Earnings

Aytu BioPharma Inc. (NASDAQ:AYTU) – Investment analysts at Ascendiant Capital Markets issued their Q1 2028 earnings per share estimates for Aytu BioPharma in a research note issued on Tuesday, September 29th. Ascendiant Capital Markets analyst E. Woo anticipates that the company will earn $0.01 per share for the quarter. Ascendiant Capital Markets has a “Buy” rating and a $14.50 price target on the stock. The consensus estimate for Aytu BioPharma’s current full-year earnings is ($0.16) per share. Ascendiant Capital Markets also issued estimates for Aytu BioPharma’s Q2 2028 earnings at $0.00 EPS, Q3 2028 earnings at $0.03 EPS, Q4 2028 earnings at $0.10 EPS and FY2028 earnings at $0.14 EPS.

AYTU has been the subject of several other research reports. Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Citigroup reiterated a “positive” rating on shares of Aytu BioPharma in a report on Tuesday, September 22nd. Finally, Weiss Ratings raised shares of Aytu BioPharma from a “sell (d-)” rating to a “sell (d)” rating in a research report on Tuesday, September 22nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $14.50.

Aytu BioPharma Stock Performance

NASDAQ AYTU opened at $2.05 on Monday. The business’s 50-day moving average price is $2.22 and its 200 day moving average price is $2.30. The company has a current ratio of 1.13, a quick ratio of 1.00 and a debt-to-equity ratio of 0.26. Aytu BioPharma has a twelve month low of $1.80 and a twelve month high of $3.07. The company has a market capitalization of $22.28 million, a PE ratio of -1.23 and a beta of 0.17.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AYTU. Dimensional Fund Advisors LP lifted its position in Aytu BioPharma by 23.3% during the first quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock valued at $119,000 after buying an additional 8,222 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Aytu BioPharma in the second quarter worth $49,000. Persistent Asset Partners Ltd acquired a new stake in shares of Aytu BioPharma in the second quarter worth $82,000. Arete Wealth Advisors LLC purchased a new position in shares of Aytu BioPharma in the 1st quarter valued at $135,000. Finally, Crown Advisors Management Inc. purchased a new position in shares of Aytu BioPharma in the 2nd quarter valued at $430,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.